Product image of Mometasona Generis (Mometasone Furoate) supplied by GNH India

Mometasona Generis

Active Ingredient:
Mometasone Furoate
Origin:
EU

Mometasona Generis (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasona Generis, is a corticosteroid presented as an inhalation product for inhalation use. It reduces airway inflammation and hyperresponsiveness, and is indicated for the management of asthma and chronic obstructive pulmonary disease in adult patients.

GNH India supplies Mometasona Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions, including compliance with EU pharmacopoeial specifications.

Manufacturer / TM Owner

Cipla Europe Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mometasona Generis, an inhaled corticosteroid, targets inflammatory pathways in chronic respiratory diseases.
  • Asthma: improves control of symptoms and reduces frequency of exacerbations.
  • COPD: decreases airway inflammation and helps prevent disease worsening.
  • Chronic bronchitis: alleviates cough and sputum production associated with airway inflammation.

How It Works

  • Mometasone furoate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the release of pro‑inflammatory cytokines, reduces eosinophil recruitment, and stabilises mast cells, leading to decreased airway edema, mucus production and hyperresponsiveness.

Side Effects

Mometasona Generis may cause a range of adverse reactions, most of which are related to its local corticosteroid activity in the respiratory tract.

Common Side Effects

  • Hoarseness or dysphonia.
  • Oral thrush (candidiasis).
  • Sore throat or irritation.
  • Cough.
  • Headache.
  • Nasal congestion.

Serious or Rare Side Effects

  • Adrenal suppression.
  • Pneumonia or severe respiratory infection.
  • Cataracts or glaucoma.
  • Severe allergic reaction (anaphylaxis).
  • Immunosuppression leading to opportunistic infections.
  • Osteoporosis with long‑term high‑dose use.

Precautions & Warnings

  • Before prescribing Mometasona Generis, clinicians should consider several safety aspects.
  • Assess infection risk: evaluate for active respiratory infections before initiating therapy.
  • Monitor growth in children: periodic assessment is recommended during long‑term use.
  • Avoid abrupt discontinuation: taper the dose to prevent adrenal insufficiency.
  • Use a spacer device: helps reduce oropharyngeal deposition and associated side effects.
  • Avoid concomitant strong CYP3A4 inhibitors: may increase systemic exposure.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Mometasona Generis can interact with other medicines that affect corticosteroid metabolism or immune function.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase systemic exposure.
  • Systemic glucocorticoids: additive immunosuppressive effects and risk of adrenal suppression.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): may raise plasma levels modestly.
  • Theophylline: corticosteroids can enhance theophylline clearance, requiring dose adjustment.
  • Live vaccines: reduced efficacy; consider timing of vaccination relative to therapy.

Frequently Asked Questions

Mometasona Generis is an inhaled corticosteroid indicated for the long‑term management of asthma and chronic obstructive pulmonary disease (COPD). It helps control airway inflammation, reduces symptom frequency, and lowers the risk of disease exacerbations when used as part of a prescribed treatment plan.

Mometasone furoate binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress inflammatory cytokines, inhibit eosinophil activity, and stabilise mast cells. This reduces airway swelling, mucus secretion, and hyper‑reactivity, improving airflow and symptom control in asthma and COPD.

The dose of Mometasona Generis is individualized by the prescribing clinician based on disease severity, patient age, and response to therapy. The prescriber determines the number of inhalations per day and the strength of each inhalation, following local guidelines and product labeling.

Safety data for mometasone furoate inhalation in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks and consider alternative therapies if safer options are available for pregnant or nursing individuals.

To request Mometasona Generis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mometasona Generis contains mometasone furoate, a high‑potency inhaled corticosteroid with strong local anti‑inflammatory activity and low systemic bioavailability. Compared with agents such as budesonide or fluticasone, it may achieve similar control at lower inhaled doses, but choice of therapy depends on individual response, device preference and physician judgment.

Mometasona Generis should be stored at room temperature, below 25 °C, in its original packaging. Keep the inhaler away from moisture, direct sunlight and heat sources. Do not freeze the product, and ensure the cap is securely closed when not in use to maintain dose integrity.

The medication is delivered via a metered‑dose inhaler. Patients should shake the inhaler, exhale fully, place the mouthpiece in the mouth, and inhale slowly while actuating the device. A spacer may be used to improve drug deposition and reduce oral side effects. Rinse the mouth after use to minimise thrush risk.

Serious risks include adrenal suppression, especially with high‑dose or prolonged use, and increased susceptibility to severe respiratory infections such as pneumonia. Rarely, patients may develop cataracts, glaucoma, or systemic immunosuppression. Any signs of severe infection, visual changes, or unexplained fatigue should prompt immediate medical evaluation.

Mometasona Generis is contraindicated in individuals with a known hypersensitivity to mometasone furoate or any component of the inhaler. It should also be avoided in patients with untreated active tuberculosis, systemic fungal infections, or those receiving systemic corticosteroids without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mometasone Furoate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT